[go: up one dir, main page]

BR0206237A - Uso de um composto de carboestiril - Google Patents

Uso de um composto de carboestiril

Info

Publication number
BR0206237A
BR0206237A BR0206237-2A BR0206237A BR0206237A BR 0206237 A BR0206237 A BR 0206237A BR 0206237 A BR0206237 A BR 0206237A BR 0206237 A BR0206237 A BR 0206237A
Authority
BR
Brazil
Prior art keywords
compound
carbon
medicament
salt
carbostyril compound
Prior art date
Application number
BR0206237-2A
Other languages
English (en)
Inventor
Shaun Jordan
Tetsuro Kikuchi
Katsura Tottori
Tsuyoshi Hirose
Yasufumi Uwahodo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0206237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR0206237A publication Critical patent/BR0206237A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"USO DE UM COMPOSTO DE CARBOESTIRIL". A presente invenção diz respeito ao uso de um composto para a produção de um medicamento para tratar de um paciente que esteja sofrendo de um distúrbio do sistema nervoso central associado com o subtipo do receptor 5-HT1A, medicamento este que compreende como um ingrediente ativo um derivado de carboestiril ou um sal deste representado pela fórmula (1): em que a ligação carbono-carbono entre as posições 3 e 4 na cadeia principal do carboestiril é uma ligação única ou dupla, e um seu sal ou solvato farmaceuticamente aceitáveis.
BR0206237-2A 2001-01-29 2002-01-29 Uso de um composto de carboestiril BR0206237A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29
PCT/JP2002/000626 WO2002060423A2 (en) 2001-01-29 2002-01-29 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists

Publications (1)

Publication Number Publication Date
BR0206237A true BR0206237A (pt) 2003-12-23

Family

ID=25087808

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206237-2A BR0206237A (pt) 2001-01-29 2002-01-29 Uso de um composto de carboestiril

Country Status (20)

Country Link
EP (3) EP1621198B1 (pt)
JP (4) JP4178032B2 (pt)
KR (5) KR100825705B1 (pt)
CN (3) CN1239154C (pt)
AR (4) AR032641A1 (pt)
AT (3) ATE322894T1 (pt)
AU (4) AU2002226752C1 (pt)
BR (1) BR0206237A (pt)
CA (2) CA2429496C (pt)
CY (3) CY1105631T1 (pt)
DE (3) DE60239711D1 (pt)
DK (3) DK1355639T3 (pt)
ES (3) ES2286755T3 (pt)
HK (2) HK1061805A1 (pt)
MX (2) MX344556B (pt)
MY (1) MY129355A (pt)
PH (1) PH12014500937A1 (pt)
PT (3) PT1621198E (pt)
TW (2) TWI331919B (pt)
WO (1) WO2002060423A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1575590B1 (en) 2002-12-27 2007-10-24 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
KR100881046B1 (ko) 2003-05-23 2009-01-30 오쓰까 세이야꾸 가부시키가이샤 기분 장애를 치료하기 위한 카르보스티릴 유도체 및 기분안정화제
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
EP1912650B8 (en) * 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
TW200848041A (en) 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
US4764416A (en) * 1986-07-01 1988-08-16 Mitsubishi Denki Kabushiki Kaisha Electric element circuit using oxidation-reduction substances
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
ES2103374T3 (es) * 1991-05-20 1997-09-16 Upjohn Co Derivados de carboxamido-(1,2n)-carbociclo-2-aminotetralina.
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
AU5446894A (en) * 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
PL188164B1 (pl) * 1996-05-07 2004-12-31 Pfizer Trihydrat metanosulfonianu 5-{2-[4-1,2-benzizotiazol-3-ilo)-1-piperazynylo]etylo}-6-chloro-1,3-dihydro-2H-indol-2-onu i środek farmaceutyczny
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
AU4091697A (en) * 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
JP2002501920A (ja) * 1998-02-03 2002-01-22 アメリカン・ホーム・プロダクツ・コーポレイション セロトニン−１ａ受容体作動薬としてのオキサゾール誘導体
WO1999052870A1 (en) * 1998-04-13 1999-10-21 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
SI1627639T1 (sl) * 2001-06-19 2010-04-30 Mueller Norbert Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
EP1355639B1 (en) 2006-04-12
MX344556B (es) 2016-12-20
WO2002060423A2 (en) 2002-08-08
DE60210581T2 (de) 2007-04-05
CN1239154C (zh) 2006-02-01
AU2002226752C1 (en) 2010-02-18
KR100763288B1 (ko) 2007-10-04
EP1712225B1 (en) 2011-04-06
PT1621198E (pt) 2007-06-08
CY1105631T1 (el) 2010-12-22
KR20070065425A (ko) 2007-06-22
MY129355A (en) 2007-03-30
KR20060085260A (ko) 2006-07-26
JP5683010B2 (ja) 2015-03-11
AU2002226752B2 (en) 2005-03-17
CN1484524A (zh) 2004-03-24
TWI302832B (en) 2008-11-11
AU2009233591A1 (en) 2009-11-19
CN100450485C (zh) 2009-01-14
KR20030065570A (ko) 2003-08-06
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
ES2286755T3 (es) 2007-12-01
EP1355639A2 (en) 2003-10-29
CA2700314C (en) 2012-04-24
CA2429496C (en) 2010-10-19
DE60210581D1 (en) 2006-05-24
HK1091403A1 (en) 2007-01-19
AU2007201701A1 (en) 2007-05-10
CY1111392T1 (el) 2015-08-05
DK1621198T3 (da) 2007-09-24
KR20060028485A (ko) 2006-03-29
AR080849A2 (es) 2012-05-09
EP1621198B1 (en) 2007-05-23
JP2007297405A (ja) 2007-11-15
KR20050107822A (ko) 2005-11-15
KR100825705B1 (ko) 2008-04-29
AU2007201701B2 (en) 2010-06-17
DE60220325T2 (de) 2008-01-17
JP2011225587A (ja) 2011-11-10
JP2004517937A (ja) 2004-06-17
JP2011184460A (ja) 2011-09-22
KR100653591B1 (ko) 2006-12-05
PT1712225E (pt) 2011-04-18
EP1621198A3 (en) 2006-04-12
CN1813745A (zh) 2006-08-09
WO2002060423A3 (en) 2003-04-10
CA2429496A1 (en) 2002-08-08
TWI331919B (en) 2010-10-21
JP4178032B2 (ja) 2008-11-12
CN1879624A (zh) 2006-12-20
DE60220325D1 (de) 2007-07-05
ATE322894T1 (de) 2006-04-15
PH12014500937A1 (en) 2015-09-21
AR032641A1 (es) 2003-11-19
EP1712225A1 (en) 2006-10-18
KR100601073B1 (ko) 2006-07-19
ES2261652T3 (es) 2006-11-16
DK1712225T3 (da) 2011-06-20
CY1108031T1 (el) 2013-09-04
PT1355639E (pt) 2006-06-30
DE60239711D1 (de) 2011-05-19
DK1355639T3 (da) 2006-08-14
HK1061805A1 (en) 2004-10-08
ATE504293T1 (de) 2011-04-15
AR099754A2 (es) 2016-08-17
AU2005201772B2 (en) 2007-05-17
JP4896831B2 (ja) 2012-03-14
EP1621198A2 (en) 2006-02-01
AU2005201772C1 (en) 2010-06-03
CA2700314A1 (en) 2002-08-08
MXPA03006603A (es) 2004-02-12
TW200522960A (en) 2005-07-16
AU2005201772A1 (en) 2005-05-19
KR100713607B1 (ko) 2007-05-02
ATE362763T1 (de) 2007-06-15
ES2363366T3 (es) 2011-08-02

Similar Documents

Publication Publication Date Title
BR0206237A (pt) Uso de um composto de carboestiril
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
LU92642I2 (fr) Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid)
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
BR0311591A (pt) 1-(aminoalquil)-2-sulfonilazindóis como ligandos de 5-hidroxitriptamina-6
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
BR0113448A (pt) Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase
BRPI0510414A (pt) uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos
BRPI0407097A (pt) Antagonista do casr
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BR0005915A (pt) Comprimido matriz que possibilita a liberação prolongada de trimetazidina após a administração pela via oral
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0308592A (pt) Derivados de piperidina ou 8-azabiciclo [3.2.1] oct-3-il-piperidina, de utilidade como moduladores da atividade do receptor de quimocina (especialmente ccr5)
BR0013793A (pt) Medicamentos profiláticos e terapêuticos para doenças oftálmicas
BRPI0410050A (pt) método de tratamento ou de profilaxia de distúrbios psicóticos, distúrbios de prejuìzo intelectual ou doenças ou condições nos quais a modulação do receptor alfa7-nicotìnico é benéfica, composição farmacêutica, método de tratamento ou de profilaxia de doenças, uso de um composto, composto, e, método de preparação de um composto
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
HK1058515A1 (en) Use of pamoic acid for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]